These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15285887)

  • 1. Summary and perspectives on kidney dose-response to radionuclide therapy.
    Wessels B
    Cancer Biother Radiopharm; 2004 Jun; 19(3):388-90. PubMed ID: 15285887
    [No Abstract]   [Full Text] [Related]  

  • 2. Introduction to kidney dose-response for radionuclide therapy.
    Sgouros G
    Cancer Biother Radiopharm; 2004 Jun; 19(3):357-8. PubMed ID: 15285882
    [No Abstract]   [Full Text] [Related]  

  • 3. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy.
    O'Donoghue J
    Cancer Biother Radiopharm; 2004 Jun; 19(3):378-87. PubMed ID: 15285886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal dosimetry in peptide radionuclide receptor therapy.
    Siegel JA; Stabin MG; Sharkey RM
    Cancer Biother Radiopharm; 2010 Oct; 25(5):581-8. PubMed ID: 20849308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical aspects of radiation nephropathy.
    Breitz H
    Cancer Biother Radiopharm; 2004 Jun; 19(3):359-62. PubMed ID: 15285883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A theoretical radiobiological assessment of the influence of radionuclide half-life on tumor response in targeted radiotherapy when a constant kidney toxicity is maintained.
    Abou-Jaoudé W; Dale R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):308-21. PubMed ID: 15285877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretherapy prediction of nephrotoxicity after peptide radionuclide receptor therapy (PRRT).
    Denardo GL; Macey DJ
    Cancer Biother Radiopharm; 2010 Oct; 25(5):507-9. PubMed ID: 20849311
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy.
    Dale R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):363-70. PubMed ID: 15285884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonuniform absorbed dose distribution in the kidney: the influence of organ architecture.
    Green A; Flynn A; Pedley RB; Dearling J; Begent R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):371-7. PubMed ID: 15285885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
    Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
    J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosage and response in radiopharmaceutical therapy of painful osseous metastases.
    Silberstein EB
    J Nucl Med; 1996 Feb; 37(2):249-52. PubMed ID: 8667054
    [No Abstract]   [Full Text] [Related]  

  • 13. Radionuclide therapy of tumors: general aspects and considerations.
    Hoefnagel CA
    Int J Biol Markers; 1993; 8(3):172-9. PubMed ID: 8277209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients?
    Konijnenberg MW
    Cancer Biother Radiopharm; 2003 Aug; 18(4):619-25. PubMed ID: 14503958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late effects of unilateral radiation on the mouse kidney.
    Jordan SW; Yuhas JM; Key CR
    Radiat Res; 1978 Nov; 76(2):429-35. PubMed ID: 752163
    [No Abstract]   [Full Text] [Related]  

  • 16. Risks to normal tissues from radionuclide therapy.
    Meredith R; Wessels B; Knox S
    Semin Nucl Med; 2008 Sep; 38(5):347-57. PubMed ID: 18662556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A quantitative technique for measuring renal damage after irradiation.
    Phillips TL; Ross G
    Radiology; 1973 Nov; 109(2):457-62. PubMed ID: 4742329
    [No Abstract]   [Full Text] [Related]  

  • 18. The influence of radiation on blood vessels and circulation. Chapter 8. Blood flow and permeability in liver, kidney and lung.
    Dunjic A
    Curr Top Radiat Res Q; 1974 Jun; 10(1):109-34. PubMed ID: 4601561
    [No Abstract]   [Full Text] [Related]  

  • 19. Sequential functional testing of radiation-induced renal damage in the mouse.
    Williams MV; Denekamp J
    Radiat Res; 1983 May; 94(2):305-17. PubMed ID: 6856776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Morpho-functional changes in the kidneys after combined exposure to UHF-field and hypoxia].
    Belokrinitskiĭ VS; Grin' AN
    Vrach Delo; 1983 Jan; (1):112-5. PubMed ID: 6868488
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.